Kintara Therapeutics, Inc. (NASDAQ:KTRA) was the target of a large growth in short interest during the month of May. As of May 28th, there was short interest totalling 1,790,000 shares, a growth of 506.0% from the May 13th total of 295,400 shares. Approximately 6.6% of the company’s stock are sold short. Based on an average daily trading volume, of 803,800 shares, the days-to-cover ratio is presently 2.2 days.
Shares of NASDAQ:KTRA traded up $0.04 during trading on Friday, hitting $1.79. 28 shares of the company were exchanged, compared to its average volume of 1,064,248. The stock has a market capitalization of $58.39 million, a PE ratio of -0.84 and a beta of 1.45. Kintara Therapeutics has a 12-month low of $0.61 and a 12-month high of $3.35. The company has a 50 day moving average of $1.47.
Kintara Therapeutics (NASDAQ:KTRA) last issued its quarterly earnings data on Friday, May 14th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.05). On average, analysts predict that Kintara Therapeutics will post -0.68 earnings per share for the current fiscal year.
About Kintara Therapeutics
Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.
Read More: Short Selling
Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.